The DiviTum TKa blood test is FDA 510(k) cleared in the US and CE marked in Europe

The DiviTum® TKa test

Unlike Any Other Blood-based Tumor Marker

The DiviTum® TKa test quantifies the level of thymidine kinase activity in the bloodstream from proliferating tumor cells. This generates a DiviTum activity score which can offer important insights about the proliferative status of a patient’s disease.

Next-Level Monitoring of mBC Patients

The DiviTum® TKa test is an innovative tumor TK activity (TKa) profile test for early prognosis and prediction of mBC treatment outcomes in postmenopausal HR+ mBC patients.1-4

Fills the Current Imaging Gap

The DiviTum® TKa test can provide clinicians with information about changes in tumor cell proliferation in response to therapy many months before a change in tumor volume is detectable by imaging.

– Assesses non-measurable disease that may not be detected with conventional imaging.
– With measurable disease, assessing TKa may complement and improve diagnostic accuracy when imaging results are equivocal.

Thymidine kinase (TK) plays a key role in DNA synthesis and cell proliferation. Studies have shown that TK activity (TKa) is elevated in actively proliferating cancer.

The DiviTum® TKa test can help health care providers determine which patients are—or are not—responding optimally to CDK4/6 inhibitor therapy and may benefit from continuing therapy.

The DiviTum® TKa test can help oncologists make confident treatment decisions

Allows health care providers to track a patient’s response early on—and at any time
point as clinically indicated throughout treatment.

Complements traditional imaging—particularly if CT scans are difficult
to interpret; assesses non-measurable disease that may not be
detected with conventional imaging

DiviTum TKa is a tool that can help guide more personalized treatment strategies for post-menopausal women diagnosed with HR+ metastatic breast cancer.


1. Bergqvist M, et al. Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226). Biomarkers January 2023

2. Paoletti C, et al. Evaluating serum thymidine kinase 1 in patients with hormone receptor-positive metastatic breast cancer receiving first-line endocrine therapy in the SWOG S0226 trial. Clin Cancer Res. 2021;27(22):6115-6123.

3. Malorni L, et al. International Breast Cancer Study Group; Breast International Group and PYTHIA Collaborators. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. Eur J Cancer. 2022;164:39-51.

4. Malorni L, et al. Serum thymidine kinase activity in patients with HRpositive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial. Eur J Cancer. 2023; 186: 1–11. Eur J Cancer 2023; 186: 1–11.


Please specify your home location